Top Markets
Coin of the day
Glenmark Life Sciences Limited Glenmark Life Sciences Limited

Glenmark Life Sciences Limited

GLS
株式のランク #7698
Glenmark Life Sciences Limited, an Indian entity established in Mumbai in 2011,... Glenmark Life Sciences Limited, an Indian entity established in Mumbai in 2011, specializes in the creation, manufacturing, and distribution of high-value active pharmaceutical ingredients (APIs). These APIs are utilized across a wide array of chronic therapeutic areas. The company's diverse portfolio includes compounds for managing cardiovascular diseases (e.g., Olmesartan, Rosuvastatin, Amiodarone), central nervous system conditions (such as Oxcarbazepine, Topiramate, Lacosamide), and diabetes (including Glimepiride, Teneligliptin, Linagliptin). Additionally, they produce APIs for pain management (Etoricoxib, Lornoxicam), gastro-intestinal disorders, anti-infective treatments, respiratory ailments, and anti-emetic applications, featuring products like Atovaquone, Fluconazole, and Esomeprazole Magnesium. Beyond API production, Glenmark Life Sciences offers contract development and manufacturing (CDMO) solutions to numerous multinational and specialty pharmaceutical firms. Operating as a subsidiary of Glenmark Pharmaceuticals Limited, the company exports its products worldwide, reaching markets in Europe, North America, Latin America, and Japan.
株価
$12.18
最終同期: 2025-02-17
時価総額
$1.49B
変化(1日)
4.21%
変化(1年)
0.00%
IN
取引 Glenmark Life Sciences Limited (GLS)

カテゴリー

Glenmark Life Sciences Limited(GLS)の配当利回りの履歴
Glenmark Life Sciences Limited(銘柄コード: GLS)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Glenmark Life Sciences Limited(GLS)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)